An association between invasive breast cancer and familial idiopathic hyperparathyroidism: A case series and review of the literature

Breast Cancer Research and Treatment

Volumn 115, Issue 1, 2009, Pages 1-5

  Pal, Sumanta Kumar ^a   Blazer, Kathleen ^a   Weitzel, Jeffrey ^a   Somlo, George ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Familial idiopathic hyperparathyroidism; MEN1; Multiple endocrine neoplasia

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MELPHALAN; METHOTREXATE; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; BREAST CARCINOMA; CANCER INVASION; CANCER RADIOTHERAPY; CASE REPORT; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HYPERPARATHYROIDISM; INTRADUCTAL CARCINOMA; MASTECTOMY; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; MULTIPLE ENDOCRINE NEOPLASIA; ONCOGENE; PRIORITY JOURNAL; REVIEW;

ADULT; BREAST NEOPLASMS; FAMILY HEALTH; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPARATHYROIDISM; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; NEOPLASM INVASIVENESS; PEDIGREE; PROTO-ONCOGENE PROTEINS;

EID: 67349168119     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0056-8     Document Type: Review

References (21)

1. G Somlo W Chow V Hamasaki 2001 Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies Biol Blood Marrow Transplant 7 5 284 293 10.1053/bbmt.2001.v7.pm11400951
2. A Jemal R Siegel E Ward 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130
3. H Heath SF Hodgson MA Kennedy 1980 Primary hyperparathyroidism incidence, morbidity and potential economic impact in the community N Engl J Med 302 4 189 193
4. SJ Marx 2005 Molecular genetics of multiple endocrine neoplasia types 1 and 2 Nat Rev Cancer 5 5 367 375 10.1038/nrc1610
5. KM Dreijerink KW Mulder GS Winkler 2006 Menin links estrogen receptor activation to histone H3K4 trimethylation Cancer Res 66 9 4929 4935 10.1158/0008-5472.CAN-05-4461
6. MD Corte F Tamargo A Alvarez 2006 Cytosolic levels of TFF1/pS2 in breast cancer: their relationship to clinical-pathological parameters and their prognostic significance Breast Cancer Res Treat 96 1 63 72 10.1007/s10549-005- 9041-7
7. P Ghataorhe AW Kurian A Pickart 2007 A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature Cancer Genet Cytogenet 179 2 89 92 10.1016/j.cancergencyto.2007.08.009
8. K Yoshimoto H Endo M Tsuyuguchi 1998 Familial isolated primary hyperparathyroidism with parathyroid carcinomas: clinical and molecular features Clin Endocrinol (Oxf) 48 67 72 10.1046/j.1365-2265.1998.00354.x
9. J Warner M Epstein A Sweet 2004 Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications J Med Genet 41 3 155 160 10.1136/jmg.2003.016725
10. RD Klein S Salih J Bessoni 2005 Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory Genet Med 7 2 131 138 10.1097/01.GIM.0000153663.62300.F8
11. IL Nilsson J Zedenius L Yin 2007 The association between primary hyperparathyroidism and malignancy: nationwide cohort on cancer incidence after parathyroidectomy Endocr Relat Cancer 14 1 135 140 10.1677/erc.1.01261
12. P Fierabracci A Pinchera P Miccoli 2001 Increased prevalence of primary hyperparathyroidism in treated breast cancer J Endocrinol Invest 24 5 315 320
13. DM Axelrod RS Bockman GY Wong 1987 Distinguishing features of primary hyperparathyroidism in patients with breast cancer Cancer 60 7 1620 1624 10.1002/1097-0142(19871001)60:7≤1620::AID-CNCR2820600733≥3.0.CO;2-3
14. B Kristensen HT Mouridsen SN Holmegaard 1989 Amelioration of postmenopausal primary hyperparathyroidism during adjuvant tamoxifen for breast cancer Cancer 64 9 1965 1967 10.1002/1097-0142(19891101)64:9≤1965::AID- CNCR2820640933≥3.0.CO;2-G
15. M Almquist J Manjer L Bondeson 2007 Serum calcium and breast cancer risk: results form a prospective cohort study of 7,847 women Cancer Causes Control 18 595 602 10.1007/s10552-007-9001-0
16. MA Birch JA Carron M Scott 1995 Parathryoid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines Br J Cancer 721 90 95
17. RP Hoey C Sanderson J Iddon 2003 The parathyroid-hormone related protein receptor is expressed in bone metastases and promotes autocrine proliferation of breast cancer cells Br J Cancer 884 567 573 10.1038/sj.bjc.6600757
18. Bianchi GV, Loibl S, Zamagni C et al (2007) Phase II multicenter trial of sorafenib in the treatment of patients with metastatic breast cancer. Proc Amer Soc Clin Oncol Breast Cancer Symposium 2007 (Abstract #164)
19. L Liu Y Cao C Chen 2006 Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 24 11851 11858 10.1158/0008-5472.CAN-06- 1377
20. Nishioka C, Ikeoze T, Yang J et al (2007) Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res (epub ahead of print.)
21. M Koyama Y Matsuzaki S Yogosawa 2007 ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen activated protein kinase/extracellular signal-regulated kinase pathway Mol Cancer Ther 6 5 1579 1587 10.1158/1535-7163.MCT-06-0814